ISPOR Europe 2024

Join us at ISPOR Europe.

We’re proudly exhibiting at this November’s ISPOR Europe in Barcelona, Spain. Our experts are looking forward to connecting at our booth, in live meetings, at our poster sessions, and more.

Where to find us.

1307

Our booth

You can find our exhibition space at #1307. Check out the ISPOR conference map for details.

20+

Poster Presentations

Engage with our experts at our featured posters for deeper dive into our work.

2

Featured Posters

One of our posters will be featured as a Top 5% abstract finalist, and another will be highlighted in a live podium presentation. Be on the look out!

The poster titles you might want to visit.

Don’t miss out on the poster sessions throughout the duration of the conference for a chance to view some of our recent work across a range of topics.

Here are some of our titles

Demonstrating the value of digital solutions in market access (Barbier S, Tournier C, Morin M, Virely N, Doghri O, Tardu J, Loomba A, Klein L, Boyce L, Sivignon M) (Mon 1030am-130pm)
Cost Effectiveness in Nanomedicines: A Small Step for Research, a Giant Leap in Value (Klimushkin N, Meunier A, Hardern C, Farrington J) (Mon 1030am-130pm)
Transporting Evidence Across Borders: A Targeted Review of the Use and Acceptability of Non-Local Data to Derive Real-World External Control Arms in Submissions to NICE (Robertshaw E, Keenan C, Leahy T, McStravick M, Sammon C, Turner A) (Mon 1030am-130pm)
From French Early Access to Reimbursement: A Comparison of Early Access Prices and List Prices (Hanna E, Dimassi M, Remuzat C, Francois C) (Mon 4-7pm)
How Is Evidence on Comparative Efficacy and Safety Presented in Japanese HTA Submissions: A Targeted Literature Review (McStravick M, Onishi Y, Kiyabu G, Turner A, Robertshaw E, Keenan C, Ikeda S) (Mon 4-7pm)
Contradictory Phase in the French Economic Appraisal: Overview and Impact on CEESP Conclusions (Doghri O, Cheylac C, Supiot R, Sivignon M) (Tue 1030-130pm)
Investigators’ Choice Comparator Arms: A Review of Their Use and Appraisal in Health Technology Assessments (McStravick M, Sammon C, Turner A) (Tue 1030-130pm)
Adverse Event (AE) Management Costs Associated With Immune Checkpoint Inhibitors (ICI) Approved for Various Advanced or Metastatic Cancers in the US (Ranjan S, Gandhi J, Mothe R, Werwath T, Ameen R, Kk M, Sagar K, Potluri R) (Tue 1030-130pm)
Recent Developments in European Voluntary Cross-Border Collaborations in Joint HTA, Drug Pricing, Procurement, and Readiness for EU HTA Implementation (Skowron R, Grioui N, Koćwin A, Dimassi M, Cork D, Remuzat C, Francois C) (Tue 1030-130pm)
Innovative Contracts: A Solution to Manage the ATMPs Associated Uncertainty (Cheylac C, Francois C, Sivignon M, Sellami R) (Tue 4-7pm)
How Are National HTA Bodies Preparing for the Implementation of the EU HTA Regulation? (Remuzat C, Koćwin A, Grioui N, Dimassi M, Cork D, Francois C) (Wed 9-1130am)
QoL Data in CAR-T Cost-Effectiveness Analysis (CEA) in France: What to Use? (Sellami R, Sivignon M) (Wed 9-1130am)

Bridging Science & Strategy^TM.

We are a leading scientific and strategic consulting partner that helps the global life science community make confident, impactful decisions and develop bespoke solutions that support bringing life-changing innovations to clinicians and patients.